Russias VTB bank apologizes for CEO who called UKs Boris Johnson a jerk
Anonymousgaryprinting.com
Will Merck & Co.s 1Q16 Earnings Match Analysts Optimism? ( Continued from Prior Part ) 1Q16 analysts’ estimates The strong performances of Merck & Co.’s (MRK) blockbuster drugs such as Januvia and Gardasil have caused analysts to estimate EPS (earnings per share) of $0.86 on sales of $9.4 billion in 1Q16. Analysts estimate EPS to be $0.90 on sales of $9.8 billion for 2Q16 and $0.98 on sales of $10.1 billion for 3Q16. MRK’s gross margin is expected to improve from 63.2% in 1Q15 to 75.7% in 1Q16. Its operating profit margin is expected to improve from 15.2% in 1Q15 to 33.6% in 1Q16. The rise in MRK’s operating margin is due to an operational fall in marketing and administration costs after MRK’s divestment of its Consumer Care business. The company’s net profit margin is expected to be around 25.6% for 1Q16, compared to 10.1% for 1Q15. Annual estimates Analysts’ estimates show EPS of ~$3.70 for 2016 and a rise in EPS to ~$3.80 for 2017. Revenue is estimated to rise by 0.7% in 2016 due to new product launches, including Keytruda’s label expansion. MRK’s gross margin is expected to rise from 63.4% in 2015 to 75.4% in 2016. It’s projected to rise to ~75.5% in 2017. The rise in MRK’s gross margin during 2016 is expected due to a lower cost of sales. MRK’s operating profit margin is expected to rise to ~34.3% in 2016 compared to 17.5% in 2015. This rise in annual operating margin is due to an operational fall in marketing and administration costs after the company’s divestment of its Consumer Care business. The Vanguard Health Care ETF (VHT) holds ~4.8% of its total assets in Merck, ~3.7% in Bristol-Myers Squibb (BMY), ~6.4% in Pfizer (PFE), and ~4.1% in Gilead Sciences (GILD). Investors can also consider ETFs such as the iShares US Healthcare ETF (IYH), which holds 5.3% of its total assets in Merck, or the MSCI Healthcare Index ETF (FHLC), which holds 4.8% of its total assets in Merck. Continue to Next Part Browse this series on Market Realist: Part 1 - Merck & Co.’s 1Q16 Estimates Show Revenue Growth Part 2 - Will Merck & Co.’s Revenue Recover Growth in 1Q16? Part 3 - Which Products Will Contribute to MRK’s Earnings Growth in 1Q16? View comments
The Fascinating Evolution of Google’s LaMDA AI and Its Waitlist Launch
Discover the latest on Google's LaMDA AI, its recent waitlist launch, and the impressive capabilities of this cutting-edge technology.